Takeda Pays ‘Upper Limit’ for Nycomed as Competition Looms

[guest]

Takeda Pharmaceutical Co. President Yasuchika Hasegawa spent four years searching for an acquisition in Europe to revive growth. The result: Nycomed, a Swiss drugmaker with falling earnings and a $9.1 billion price tag.


More...

Toggle signature
||||| Mentor Group Access Now! |||||